IL-33: a potential therapeutic target in autoimmune diseases.
Interleukin 33 (IL-33) is a newly described member of the IL-1 superfamily of cytokines. Through activation of the ST2 receptor, which is widely expressed particularly by helper T 2 cells and mast cells, IL-33 is involved in T-cell-mediated immune responses. Many previous studies have demonstrated that IL-33 may have a pleiotropic function in different diseases, and it could represent a novel target for the treatment of a range of diseases. Recent works have explored the role of IL-33 in chronic autoimmune diseases, such as systemic sclerosis, inflammatory bowel disease, rheumatoid arthritis, and systemic lupus erythematosus. These results indicate that IL-33 may contribute to the pathogenesis of chronic autoimmune diseases. Hence, in this review, we discuss the biological features of IL-33 and summarize recent advances on the role of IL-33 in the pathogenesis and treatment of autoimmune diseases.
Medical Administration Department, The Second Hospital of Anhui Medical University, Anhui, PR China.
Song
S
Wang
Lei
L
Ding
Shan-Shan
SS
Liu
Chao
C
Wang
Rui-Xue
RX
Leng
Gui-Mei
GM
Chen
Yin-Guang
YG
Fan
Hai-Feng
HF
Pan
Dong-Qing
DQ
Ye
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000378:metabolism; D000067596:Interleukin-33; D007378:Interleukins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
C506536:IL33 protein, human; D007155:Immunologic Factors; D000067596:Interleukin-33; D007378:Interleukins